wsbdaily | Wed, 10 Aug 2022 07:32:32 EST Where you find Tomorrow’s Hot Stocks Yesterday!
NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
CVRx, Inc.(CVRX)
CVRx, Inc.
9201 West Broadway Avenue
Suite 650
Minneapolis, MN 55445
United States
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe,... Read More
Summary & Charts
| Price | $ 8.83 | +1.28 (+16.95%) |
| Day's Range | $ 7.75 - 9.19 | |
| Previous Close | $ 7.55 | |
| Market Cap | $ 181.69M USD | |
| Short Interest % | N/A | |
| Float | N/A | |
| Outstanding | N/A |
| Exchange | NasdaqGS | |
| Industry | Medical Devices | |
| Sector | Healthcare | |
| Volume | 246.82K | |
| Avg. Volume (20 day) | 57.25K | |
| Rel. Volume (20 day) | 4.31 | |
| Rel. Volume (3 month) | 2.24 | |
| Rating | B+ | Neutral |
| DCF | N/A | Strong Buy |
| Debt/Equity | 5.56 % | Neutral |
| ROE | -148.64 % | Neutral |
| ROA | -30.78 % | Neutral |
| P/E | -4.06 % | Strong Sell |
| P/B | 1.32 % | Buy |
| Date | Open | High | Low | Close | Change | Volume | R. Vol. (20d) | R. Vol. (3m) | Mentions |
|---|---|---|---|---|---|---|---|---|---|
| Jul 29, 2022 | $ 7.94 | $ 9.19 | $ 7.75 | $ 8.83 | +1.28 | 246,822 | 4.31 | 2.24 | |
| Jul 28, 2022 | $ 7.27 | $ 7.64 | $ 7.07 | $ 7.55 | +0.32 | 34,591 | 0.73 | 0.27 | |
| Jul 27, 2022 | $ 7.44 | $ 7.44 | $ 7.08 | $ 7.23 | -0.07 | 35,406 | 0.72 | 0.26 | |
| Jul 26, 2022 | $ 7.29 | $ 7.34 | $ 7.05 | $ 7.30 | -0.09 | 32,645 | 0.66 | 0.24 | |
| Jul 25, 2022 | $ 7.18 | $ 7.40 | $ 7.18 | $ 7.39 | +0.16 | 20,639 | 0.38 | 0.15 | |
| Jul 22, 2022 | $ 7.75 | $ 7.75 | $ 7.11 | $ 7.23 | -0.47 | 41,874 | 0.38 | 0.30 | |
| Jul 21, 2022 | $ 7.29 | $ 7.70 | $ 7.10 | $ 7.70 | +0.42 | 52,300 | 0.45 | 0.37 | |
| Jul 20, 2022 | $ 7.07 | $ 7.35 | $ 7.07 | $ 7.28 | +0.28 | 32,000 | 0.27 | 0.23 | |
| Jul 19, 2022 | $ 7.15 | $ 7.20 | $ 6.90 | $ 7.00 | -0.06 | 73,900 | 0.60 | 0.52 | |
| Jul 18, 2022 | $ 7.23 | $ 7.57 | $ 7.02 | $ 7.06 | +0.28 | 113,300 | 0.85 | 0.80 | |
| Jul 15, 2022 | $ 6.86 | $ 6.96 | $ 6.66 | $ 6.78 | +0.06 | 56,000 | 0.40 | 0.40 | |
| Jul 14, 2022 | $ 6.34 | $ 6.78 | $ 6.07 | $ 6.72 | +0.34 | 42,600 | 0.30 | 0.30 | |
| Jul 13, 2022 | $ 6.30 | $ 6.48 | $ 6.30 | $ 6.38 | 62,400 | 0.44 | 0.44 | ||
| Jul 12, 2022 | $ 6.53 | $ 6.53 | $ 6.35 | $ 6.38 | -0.08 | 31,300 | 0.22 | 0.22 | |
| Jul 11, 2022 | $ 6.70 | $ 6.75 | $ 6.42 | $ 6.46 | -0.24 | 21,400 | 0.15 | 0.15 | |
| Jul 08, 2022 | $ 6.84 | $ 6.95 | $ 6.66 | $ 6.70 | -0.07 | 46,000 | 0.30 | 0.31 | |
| Jul 07, 2022 | $ 6.45 | $ 6.82 | $ 6.38 | $ 6.77 | +0.40 | 54,800 | 0.35 | 0.37 | |
| Jul 06, 2022 | $ 6.53 | $ 6.62 | $ 6.30 | $ 6.37 | -0.12 | 25,700 | 0.16 | 0.17 | |
| Jul 05, 2022 | $ 5.99 | $ 6.71 | $ 5.99 | $ 6.49 | +0.37 | 74,200 | 0.45 | 0.49 | |
| Jul 01, 2022 | $ 6.06 | $ 6.38 | $ 5.88 | $ 6.12 | +0.11 | 47,200 | 0.29 | 0.31 |
News
The latest news about CVRx, Inc. (CVRX).
Seeking Alpha | 2022-07-29 15:07:03
CVRx, Inc. (NASDAQ:CVRX ) Q2 2022 Earnings Conference Call July 28, 2022 5:30 PM ET Company Representatives Nadim Yared - President, Chief Executive Officer Jared Oasheim - Chief Financial Officer Mike Vallie - Westwicke, ICR Company Conference Call Participants Matthew O'Brien - Piper Sandal Margaret Kaczor - William Blair Alex Nowak - Craig-Hallum William Plovanic - Canaccord Operator Good day and thank you for standing by. Welcome to the CVRx Second Quarter 2022 Earnings Conference Call.
GlobeNewsWire | 2022-07-29 08:30:00
MINNEAPOLIS, July 29, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022. The Company is scheduled to present at 8:30 am Eastern Time the same day via webcast.
Zacks Investment Research | 2022-07-28 19:30:36
CVRx (CVRX) delivered earnings and revenue surprises of 0% and 6.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire | 2022-07-14 16:30:00
MINNEAPOLIS, July 14, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2022 financial and operating results after market close on Thursday, July 28th, 2022. The Company will host a conference call to review its results at 5:30 p.m. Eastern Time the same day.
Zacks Investment Research | 2022-06-27 10:46:00
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
GlobeNewsWire | 2022-05-23 16:30:00
MINNEAPOLIS, May 23, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the William Blair 42nd Annual Growth Stock Conference on Monday, June 6, 2022. The Company is scheduled to present at 3:20 pm Central Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at ir.cvrx.com. A replay of the webcast will be archived on the website for approximately 90 days. About CVRx, Inc. CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Earnings
| Date | Time | EPS Expected | EPS Reported | % | Revenue Expected | Revenue Reported | % |
|---|---|---|---|---|---|---|---|
| 2022-07-28 | AMC | -0.54 | -0.54 | -- | 4.7M | -- | -- |
| 2022-05-17 | AMC | -0.49 | -- | -- | 4.1M | 4.1M | -0.35% |
| 2022-04-25 | AMC | -0.49 | -0.49 | -- | 4.1M | 4.1M | -0.35% |
| 2022-02-15 | AMC | -0.43 | -0.52 | 20.93% | 4.1M | 3.7M | -10.57% |
| 2021-11-04 | AMC | -0.38 | -0.30 | 21.06% | 3.3M | 3.4M | 3.5% |
| 2021-08-04 | AMC | -21.27 | -48.48 | 127.92% | 2.2M | 3.1M | 44.67% |
Top Discussions
These are the top discussions over the last 24-hours that mention the CVRX stock ticker symbol.
Failures to Deliver
Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.
Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.
Last Updated: Tue, 14 Dec 2021 12:00 EST
@wsbdaily
wsbdaily